Search results
Results From The WOW.Com Content Network
Factor X. Coagulation factor X (EC 3.4.21.6), or Stuart factor, is an enzyme of the coagulation cascade, encoded in humans by F10 gene. [5] It is a serine endopeptidase (protease group S1, PA clan). Factor X is synthesized in the liver and requires vitamin K for its synthesis.
Factor Xa inhibitors are newer anticoagulants that don’t require people to take frequent blood tests. You take factor Xa inhibitors to prevent or treat blood clots.
Factor Xa inhibitors are a type of anticoagulant, or blood thinner. They’re a short- and long-term therapy for venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and...
Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III ...
The prothrombinase enzyme complex consists of factor Xa (a serine protease) and factor Va (a protein cofactor). The complex assembles on negatively charged phospholipid membranes in the presence of calcium ions.
Andexanet alfa is a modified recombinant inactive form of human factor Xa, which binds and sequesters factor Xa inhibitor molecules, rapidly reducing anti–factor Xa activity and restoring ...
Coagulation factor Xa is used to treat uncontrolled bleeding in people who take the anticoagulants rivaroxaban (Xarelto) and apixaban (Eliquis). Coagulation factor Xa was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis.
Activated factor Xa (FXa) is traditionally known as an important player in the coagulation cascade responsible for thrombin generation. Long considered a passive bystander, it is now evident that FXa exerts direct effects on a wide variety of cell types via activation of its two main receptors, protease-activated receptor-1 (PAR-1) and PAR-2.
Factor Xa (FXa) plays a key role in haemostasis, it is a central part of the blood coagulation cascade which catalyzes the production of thrombin and leads to clot formation and wound closure. Therefore, FXa is an attractive target for the development of new anticoagulant agents.
Factor Xa is a serine protease involved in coagulation. Its actions at the PAR1 and PAR2 receptors depend upon cofactors including tissue factor and factor VIIa. In the initiation of coagulation, factor Xa associates with factor VIIa and tissue factor to form a TF-VIIa-Xa complex Riewald and Ruf (2002).